NASDAQ:MCRB

Seres Therapeutics Stock Forecast, Price & News

$20.73
-0.66 (-3.09 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$20.16
Now: $20.73
$21.34
50-Day Range
$17.66
MA: $20.15
$22.70
52-Week Range
$3.41
Now: $20.73
$38.50
Volume664,843 shs
Average Volume1.04 million shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.07
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626
Employees155
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.51 million
Book Value($0.69) per share

Profitability

Net Income$-70,280,000.00
Net Margins-385.22%

Miscellaneous

Market Cap$1.90 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Seres Therapeutics (NASDAQ:MCRB) Trading Up 4.9%
April 13, 2021 |  americanbankingnews.com
Seres Therapeutics (NASDAQ:MCRB) Shares Gap Down to $20.61
April 6, 2021 |  americanbankingnews.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Up 6%
March 30, 2021 |  americanbankingnews.com
MCRB Crosses Below Key Moving Average Level
March 16, 2021 |  nasdaq.com
Is MCRB A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
News for Seres Therapeutics Inc
November 26, 2020 |  markets.businessinsider.com
Seres Therapeutics: Microbiomics Back In The Game
November 13, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

193rd out of 2,021 stocks

Pharmaceutical Preparations Industry

86th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$20.73
-0.66 (-3.09 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Seres Therapeutics?

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Seres Therapeutics
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings results on Monday, March, 1st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. The biotechnology company earned $17.56 million during the quarter, compared to analysts' expectations of $8.78 million. Seres Therapeutics had a negative net margin of 385.22% and a negative trailing twelve-month return on equity of 2,867.98%.
View Seres Therapeutics' earnings history
.

How has Seres Therapeutics' stock price been impacted by COVID-19?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 685.2% and is now trading at $20.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MCRB?

7 analysts have issued 12-month target prices for Seres Therapeutics' stock. Their forecasts range from $29.00 to $49.00. On average, they anticipate Seres Therapeutics' stock price to reach $38.17 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price.
View analysts' price targets for Seres Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:
  • Mr. Eric D. Shaff M.B.A., Pres, CEO & Director (Age 45, Pay $801.4k)
  • Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 46, Pay $530.4k)
  • Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 66, Pay $597.7k)
  • Mr. Marcus Chapman, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 50)
  • Dr. David S. Ege Ph.D., Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
  • Mr. Jeff York, VP of HR
  • Ms. Jayne M. Gansler, Exec. VP & Chief People Officer
  • Dr. John G. Aunins, Sr. Advisor (Age 60)
  • Mr. James R. Weston, Sr. VP of Regulatory Affairs

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), 1877 (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FDx Advisors Inc. (0.01%), Phoenix Wealth Advisors (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Seres Therapeutics stock include Marcus Chapman and Noubar Afeyan.
View institutional ownership trends for Seres Therapeutics
.

Which major investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Phoenix Wealth Advisors, Pacer Advisors Inc., and FDx Advisors Inc..
View insider buying and selling activity for Seres Therapeutics
or view top insider-selling stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $20.73.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $1.90 billion and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 155 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.